Accord Healthcare has launched an app to support cancer patients and help manage symptoms, incorporating expert data from Macmillan Cancer Support.

Amneal is setting its sights on the migraine and cluster headache market in the US with a new hybrid 505(b)(2) filing for a dihydroergotamine autoinjector.

With a looming entry deadline of 30 July, companies have a little under two months to enter the Global Generics & Biosimilars Awards 2021, ahead of the awards ceremony on 10 November.

Zentiva has announced that it is investing a further €27m in expanding its flagship manufacturing plant in Prague, having already pumped €35m into the site over the past three years.

Eagle Pharmaceuticals has received approval for a new indication in Japan for its Treakisym (bendamustine) used to diffuse large B-cell lymphoma. The company is looking to expand as it expects the new indication to generate an opportunity worth up to $25m.

Hyloris is on a roll with licensing deals for its Maxigesic IV non-opioid pain treatment, with an extension of its existing agreement with Pharma Bavaria to cover South American territories coming hot on the heels of recent developments in the US and Europe.